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Abstract Lipoprotein lipase (LPL) is a complex enzyme con- 
sisting of multiple functional domains essential for the initial 
hydrolysis of triglycerides present in plasma lipoproteins. Previ- 
ous studies have localized the catalytic domain of LPL, responsi- 
ble for the hydrolytic function of the enzyme, to the N-terminus 
whereas the C-terminal end may play a role in lipid and heparin 
binding. To date, most described missense mutations resulting 
in a nonfunctional LPL have been located in the N-terminal 
region of the enzyme. In this manuscript we describe the defect 
in the LPL gene of a patient with triglycerides ranging from nor- 
mal to 12,000 mg/dl, low LPL mass, and no LPL activity in post- 
heparin plasma. Sequencing of patient PCR-amplified DNA 
identified two separate mutations in the C-terminal domain of 
LPL: an A -+ T transversion at nucleotide 1484 resulting in a 
G l ~ ~ ~ o - V a l  substitution and a C-+G mutation at position 1595 
that introduces a premature stop codon at position 447. Diges- 
tion with Mae111 and MnII established that the patient is a true 
homozygote for both mutations. In order to investigate the func- 
tional significance of these defects, mutant enzymes containing 
either the Val4Io or the Ter447 mutations as well as both Val410 
and Ter447, were expressed in vitro. Compared to the wild-type 
enzyme, LPL447 demonstrated a moderate reduction of specific 
activity using triolein (70% of normal) and tributyrin (74% of 
normal) substrates, while LPL4Io had a significant (11% and 
23% of normal) reduction of the normal lipase and esterase 
specific activities, respectively. M U ~ ~ ~ ~ - L P L ~ ~ " ' ~ ' '  was virtually 
inactive using either triolein or tributyrin substrates establishing 
the functional significance of this combined defect. When ana- 
lyzed by heparin-Sepharose affinity chromatography, a small 
fraction of LPL4'O, like the native LPL dimer, eluted at an NaCl 
concentration of 1.3 M and had a normal specific activity. 
However, most of the LPL4lo mass was detected in an inactive 
peak that, like the normal LPL-monomer, eluted at 0.8 M 
NaCI, indicating that the Glu410+Val substitution may alter the 
stability of the LPL dimer. 8lI In summary, we have identified 
a unique mutation in the C-terminal domain of LPL that 
significantly affects the function of the mutant enzyme. Despite 
its location in the C-terminal domain of LPL, this mutation does 
not directly disrupt the heparin-binding properties of the mu- 
tant enzyme or its ability to interact with or hydrolyze either 
lipid or water-soluble substrates. Instead, the loss of enzyme aL- 
tivity appears to be related to a change in the monomer-dimer 
equilibrium of the mutant enzyme. Our  studies indicate that, in 
addition to the proposed role in the lipid binding function, the 
C-terminal domain may play an important role in the formation 
of the active LPL dimer.-Previato, L., 0. Guardamagna, K. A. 
Dugi, R. Ronan, G. D. Talley, S. Santamarina-Fojo, and H. B. 
Brewer, Jr. A novel missense mutation in the C-terminal do- 
main of lipoprotein lipase (Glu410-+Val) leads to enzyme inacti- 
vation and familial chylomicronemia. J Lipid Res. 1994. 35: 
1552-1560. 
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Lipoprotein lipase (LPL) is a 55-kD glycoprotein that 
plays a major role in the hydrolysis of triglycerides present 
in  chylomicrons and very low density lipoproteins 
(VLDL) (1). LPL is produced primarily by adipose tissue, 
heart and  skeletal muscle, macrophages, and lactating 
m a m m a r y  gland a n d  is bound,  in  its active homodimeric 
form, to the luminal surface of vascular endothelium (2). 
The importance of LPL in triglyceride hydrolysis has  
been established by the identification of patients with a 
deficiency of LPL.  Affected individuals present with the 
familial chylomicronemia syndrome, a rare autosomal 
recessive disorder, characterized by accumulation of 
chylomicrons i n  fasting plasma a n d  massive elevation of 
plasma triglycerides. T h i s  metabolic defect is often as- 
sociated with recurrent episodes of abdominal pain o r  
pancreatitis in infancy or childhood, hepatosplenomegaly, 
eruptive cutaneous xanthomas, and lipemia retinalis (2 ,  3). 
. ~~~~ 
Abbreviations: LPL. lipoprotein lipase; PCR, polymerase chain reac- 
tion; PL, pancreatic lipase; apC-11, apolipopmtein C-11; HL, hepatic lipase. 
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The cDNA and genomic organization of the LPL gene 
have been previously described (4-7). The high degree of 
primary amino acid sequence homology as well as 
similarity of genomic organization between LPL and 
hepatic (HL) and pancreatic lipase (PL) indicate a com- 
mon evolutionary origin for these three enzymes (6) and 
suggest that the three lipases share analogous structural 
domains with similar secondary and tertiary structures 
(8, 9). Analysis of the three-dimensional crystallographic 
structure of human PL described by Winkler, DArcy, and 
Hunziker (10) indicates that PL contains two major struc- 
tural domains. The amino-terminal region consists of an 
alp structure dominated by a central parallel &sheet and 
a C-terminal domain containing a 0-sandwich structure 
formed by two 0-sheets of four antiparallel strands each. 
By analogy to PL, LPL has also been proposed to consist 
of two structurally distinct regions consisting of an N- 
terminal and a C-terminal domain. Recent studies involv- 
ing site-directed mutagenesis of LPL (11, 12) and the syn- 
thesis of chimeric lipases between LPL and HL (13, 14) 
have localized the catalytic domain as well as the site of 
apoC-I1 interaction to the N-terminal region of LPL. In 
addition, the N-terminal domain contains a loop covering 
the catalytic site of the enzyme that appears to be impor- 
tant for the interaction of LPL with its lipid substrate (15). 
Recent studies have indicated that the C-terminal domain 
of LPL may play a role in mediating heparin binding as 
well as the interaction of the enzyme with its lipid sub- 
strate (13, 14). However, the functional role of the C- 
terminal domain of LPL remains to be definitively estab- 
lished. Although most of the mutations identified in the 
LPL gene (16, 17) have been located in the N-terminal 
region of the enzyme, three mutations involving the C- 
terminal domain have been described. These defects 
result in the synthesis of truncated mutants LPL382 (18) 
and LPL447 (19) as well as LPL334 (20) which contains an 
Ala+Thr substitution at residue 334. The functional 
significance of LPL334, however, remains to be established. 
In this report we describe the molecular defect leading 
to a functional deficiency of LPL in a patient presenting 
with the familial chylomicronemia syndrome. The patient 
is homozygous for a unique missense mutation that 
results in the substitution of valine for glutamic acid at 
residue 410. This defect represents the first amino acid 
substitution described in the carboxyl-terminus of LPL 
that has been functionally demonstrated by in vitro 
studies to result in a severe loss of activity of the enzyme. 
Additionally, the proband is also homozygous for the 
previously described Ser447-+Ter mutation. In vitro ex- 
pression of LPL4'0 and LPL447 results in the production 
of mutant enzymes with reduced specific triolein hydro- 
lytic activity (11% and 70% of normal LPL, respectively). 
The combined presence of both Val4lo and Ter447 muta- 
tions completely inactivates LPL, establishing the func- 
tional significance of these defects. 
MATERIALS AND METHODS 
Clinical data 
The proband is a 3-year-old male of Egyptian descent 
who presented at age 2 months with acute pancreatitis 
and hepatosplenomegaly. Plasma lipid analysis revealed 
chylomicronemia with plasma triglyceride and cholesterol 
levels of greater than 12,000 mg/dl and 1,100 mg/dl, 
respectively. During the hospitalization the patient 
responded favorably to a blood transfusion and lipid-free 
parenteral nutrition. Diagnosis of LPL deficiency was es- 
tablished by demonstrating the absence of LPL activity 
assayed in post-heparin plasma in the presence of ex- 
ogenous apolipoprotein C-11. Eruptive cutaneous xan- 
thomas and lipemia retinalis have never been described 
and no other episodes of pancreatitis have been reported. 
The patient, who shows normal physical and intellectual 
development, is currently on a low fat diet (15% of total 
caloric intake) supplemented with medium-chain 
triglyceride oil. There is no history of consanguinity in 
the family. 
Quantitation of post-heparin plasma HL activity and 
LPL activity and mass 
Blood was collected in EDTA tubes before and 10 min 
after an intravenous bolus of heparin was administered at 
60 units/kg body weight. LPL and HL lipolytic activities 
were assayed in triplicate using a radiolabeled triacyl- 
glycerol-phosphatidylcholine emulsion as previously 
reported (21). LPL and HL activities in post-heparin 
plasma were determined by selectively blocking LPL with 
1 M NaCl. LPL mass was measured by an ELISA using 
the monoclonal antibody 5D2 (22), and the chicken poly- 
clonal anti-human LPL polyclonal antibody as described 
previously (23). 
DNA analysis 
Genomic DNA was extracted from leukocytes isolated 
from the proband and his parents (24). The coding se- 
quence of LPL and the intron-exon junctions were am- 
plified by the polymerase chain reaction using intronic 
primers as previously reported (25, 26). The downstream 
primer used for the amplification of part of exon 10 an- 
nealed at base 1622-1645 of the published cDNA se- 
quence (4). DNA analysis was performed using a combi- 
nation of double-stranded DNA sequencing from 
pGEM7 vector (Promega Corp., Madison, WI) or direct 
PCR sequencing as described below. After the first stan- 
dard PCR the product was gel purified in low melting 
point agarose and approximately 100 ng of the purified 
fragment was reamplified in an asymmetric polymerase 
chain reaction (PCR) using an unequal molar ratio 
(1/100) of the same primers (27). After filtration using a 
Centricon 100 microconcentrator (Amicon Corp., Dan- 
vers, MA) the product of the second PCR was sequenced 
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with the dideoxy-nucleotide chain termination method 
(28) using Sequenase (United States Biochemicals, 
Cleveland, OH) for single-stranded DNA sequencing. 
Restriction analysis of PCR-amplified exons 8 and 9 was 
performed by digestion with Mae111 (Boehringer Mann- 
heim, Germany) and MnII (New England Biolabs, 
Beverly, MA). The resulting DNA fragments were ana- 
lyzed on a 3% agarose minigel. 
LPL cDNA expression vectors 
The normal human LPL cDNA construct, designated 
pCMV-NL, has been described previously (29). It con- 
tains the cytomegalovirus early promoter driving the ex- 
pression of a 1470 bp fragment of the LPL cDNA span- 
ning the signal peptide through the termination codon. 
The mutant LPL cDNAs, pCMV-410, pCMV-447, and 
pCMV-410-447, were generated from the pCMV-NL con- 
struct by site-directed mutagenesis using the overlap ex- 
tension method (30), and DNA sequence analysis of the 
constructs was performed by the dideoxynucleotide chain 
termination method (28). Large-scale preparation of the 
normal and mutant LPL constructs was performed by 
double equilibrium centrifugation in CsCl (31). 
In vitro expression 
Human embryonic kidney 293 cells (ATCC, Rockville, 
MD) were transfected with 40 pg plasmid DNA/lOO-mm 
dish using the calcium phosphate co-precipitation method 
(32). After 24 h of incubation with cells, media sup- 
plemented with 2 unitdm1 sodium heparin (Lipho Med, 
Melrose Park, IL) were harvested. Cell extract was pre- 
pared as previously described (33). Cells, washed and 
scraped in phosphate-buffered saline, were lysed and soni- 
cated in 0.22 M Tris-HC1, pH 8.5, 0.25 M sucrose, 10 
mg/ml BSA, 50 pg/ml heparin, 0.2% Nadeoxycholate, 
and 0.008% (v/v) Nonidet P40. Culture media, sup- 
plemented with glycerol at a final concentration of 30% 
(v/v), as well as cell extracts were aliquoted, flash-frozen, 
and stored at -70°C for determination of LPL mass. 
One aliquot was kept unfrozen and LPL activity was as- 
sayed in triplicate 2 h after harvesting as previously 
described (21). LPL lipolytic activity was also measured 
using tributyrin as a hydrosoluble substrate (34). 
Heparin-Sepharose affinity chromatography 
Affinity chromatography of conditioned media from 
cells transfected with normal and mutant LPL was per- 
formed as described by Ostlund-Lindqvist and Boberg 
(35). Ten ml of transfected media was applied to a 1-ml 
column of heparin-Sepharose CL-6B (Pharmacia-LKB 
Biotechnology, Uppsala, Sweden) at 15.6 mVcm2 per h. 
The unbound protein was eluted with 10 ml 0.4 M NaCl 
in 0.01 M sodium phosphate, pH 7.4, 0.1% CHAPS, and 
30% glycerol. The column was then developed with a 
30-ml linear gradient to 2.0 M NaCl in 0.01 M sodium 
phosphate, pH 7.4, 0.1% CHAPS, and 30% glycerol. 
One-ml fractions containing 2 USP units of sodium hepa- 
rin were assayed for enzyme mass and activity. NaCl con- 
centration of alternating fractions was monitored with a 
Radiometer conductivity meter at 5O-7OC. The conduc- 
tivities were then related to a theoretical linear curve of 
NaCl concentrations of the developing and limiting buffer 
of the gradient. For calculation of LPL4Io specific activity, 
ten 1-ml fractions eluting at 1 M to 1.5 M were pooled, 
concentrated using Centricon 30 (Amicon, Gorp., Dan- 
vers, MA), and assayed for LPL mass and activity as indi- 
cated. 
RESULTS 
Table 1 summarizes the biochemical profile of fasting 
plasma samples obtained from the proband and his par- 
ents. While the patient observed a strict low-fat diet his 
triglycerides were moderately elevated, total cholesterol 
(C) was normal, and high density lipoprotein (HDL)-C 
was markedly decreased. Apolipoprotein C-I1 plasma 
levels (3.4 mg/dl) were normal as was the apparent 
molecular weight of apoC-I1 on two-dimensional elec- 
trophoresis (data not shown). The patient's apoE pheno- 
TABLE l .  Biochemical profile of fasting plasma samples from the patient and his parents 
Lipids and Lipoproteins Lipase Activity LPL Mass 
Total VLDL LDL HDL 
Subject TC TG TC ' I C  TC TC LPL H L  Pre Post 
r n / n l  nmol/ml/mzn a d m l  
Proband 113 4 7 i  5 3  425 44 16  0 415 0 55 
Father 151 125 16 72 87 43 199 171 0 450 
Mother 194 172 24 125 137 33  187 616 0 622 
TC, total cholesterol; 'TG, triglyceride; VLDL, very low density lipoprotein; LDL, low density lipoprotein; HDL, 
high density lipoprotein; LPL, lipoprotein lipase; HL,  hepatic lipase. 
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type was E3/E3. The plasma lipid, lipoprotein, and 
apolipoprotein values as well as lipase activities of the 
father were normal, while the mother had slightly 
elevated triglycerides and low levels of HDL-C. The LPL 
concentration in the patient’s post-heparin plasma (Table 
1) was significantly reduced and LPL activity was un- 
detectable. The HL activity in the proband’s post-heparin 
plasma was within the normal range. 
Analysis of the proband’s LPL gene by both direct PCR 
sequencing as well as sequence analysis of six indepen- 
dent clones obtained from PCR amplification of the LPL 
exons revealed the presence of a transversion, A+T, at 
position 1484 in the eighth exon, resulting in a Glu+Val 
substitution at residue 410 of the mature LPL. Autoradi- 
ography of DNA sequencing gels illustrating the patient’s 
A+T substitution as well as the normal LPL sequence is 
shown in Fig. 1. DNA sequence analysis revealed the 
presence of a second mutation, a C+G transversion in 
exon 9 at nucleotide position 1595, which introduces a 
premature termination codon at Ser44’, resulting in the 
synthesis of a truncated LPL missing 2 amino acid 
residues at the carboxyl terminus. The mutation at codon 
447 of LPL has been previously described in heterozygous 
and homozygous normolipidemic healthy subjects (36, 
37) as well as in one hypertriglyceridemic patient (19). 
The A+T and C+G transversions generate new res- 
triction sites for MaeIII and MnII, respectively, in the pa- 
tient’s LPL gene. Figure 2A illustrates the restriction pat- 
tern expected when the normal and the mutant amplified 
exon 8 are digested with MaeIII. Amplification of exon 8 
results in the synthesis of a 233 bp product (Fig. 2A, lane 
1). Digestion of the mutant exon 8 with MaeIII generates 
two fragments of 194 and 39 bp (Fig. 2A, lane 3), while 
digestion of the normal exon 8 (Fig. 2A, lane 2), which 
has no MaeIII sites, does not alter the size of the am- 
plification product. Mae11 digestion of PCR-amplified 
DNA from either parent (Fig. 2A, lanes 4 and 5) resulted 
in the formation of normal (233 bp) as well as abnormal 
(194 bp and 39 bp) fragments consistent with their status 
as obligate heterozygotes. The G+C transversion creates 
a new restriction site for MnII in the patient’s gene. Fig. 2B 
illustrates the restriction enzyme pattern of the amplified 
exon 9 from the proband, family members, and a normal 
control after digestion with MnII. As expected, the size of 
amplified control DNA (Fig. 2B, lane 2) was not modified 
by MnII digestion. Incubation of patient amplified DNA 
with MnII resulted in the formation of two fragments of 
125 and 53 bp in length (Fig. 2B, lane 3). The presence 
of all three fragments (53, 125, and 178 bp) after digestion 
of the parents’ amplified DNA with MnII (Fig. 2B, lanes 
4 and 5) is consistent with their status as obligate heter- 
ozygotes. Thus, the patient is a true homozygote for both 
gene defects. 
Despite the loss of a negative charge resulting from the 
. I  3’ LPL GENE 
Exon NO. 1 2 3 4 5  6 10 
5’ 
3’ 
A 
m 3’ A cln. w P -Lys 
A -Gln 
CT-Thr 
LI 
a B  
.L 
mb 
+ 
A A A-Lys  
5’ 5’ 
NORMAL PATlE N T 
Fig. 1. Autoradiography of DNA sequencing gels illustrating the normal LPL sequence and the patient’s mutation. The genomic organization of 
the LPL gene is illustrated on top. Autoradiography of the sequencing gels of DNA from a normal subject and the patient illustrating the A to T 
substitution in codon 410 of the patient’s LPL gene. 
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N O R M A L  M a e  111 
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PATTERN 
PATIENT M a e  111 
233bp 
* 194bp-+gbA ~ ~ ~ ~ ~ c ~ I o  
M 
M 1 2 3 4 5  
Exon 9 
B 
5' I+/ -/-I 3' - 
Primer A Prime, B 
I- N O R M A L  M n l  I RESTRICTION 178bp PATTERN 
1-125bp-1-53b~J PATTERN 
PATIENT M n l  I 
RESTRICTION 
M 
- 178bp - 125bp 
M 1 2 3 4 5  
Fig. 2. Restriction enzyme analysis of the amplified exons 8 and 9 from the patient, family members, and a normal control. Panel A: Expected 
MaeIII restriction pattern of PCR-amplified exon 8 for normal LPL DNA and DNA containing the patient's mutation. The agarose gel on the bottom 
illustrates the size of undigested PCR-amplified exon 8 (lane l), as well as PCR-amplified exon 8 from control DNA (lane 2), the patient's DNA (lane 
3), and DNA from either parent (lanes 4 and 5) after digestion with MaeIII. Panel B: Expected MnII restriction pattern of PCR-amplified exon 9 
for normal and patient DNA. The agarose gel illustrates undigested PCR-amplified exon 9 (lane 1) and PCR-amplified exon 9 from normal control 
(lane 2). patient (lane 3), and parent (lanes 4 and 5) DNA after digestion with MnII. 
Val410 mutation, computer analysis (PC Gene, Intel- 
liGenetics, Mountain View, CA) performed by the 
methods of Novotny and Auffray (38), Chou and Fasman 
(39), and Garnier, Osguthorpe, and Robson (40) on the 
mutated protein sequences to examine for changes in 
hydrophilicity, hydrophobicity and secondary structure 
did not predict any significant differences between the 
normal and the mutant LPLs containing one or both mu- 
tations (data not shown). 
In order to test the functional significance of the 
Gluq10+Val and the Ser447+Ter mutations, expression 
plasmids encoding for the normal and the mutant LPLs 
were transfected into human embryonal kidney 293 cells. 
The media and cellular extracts were then assayed for 
LPL activity and mass. LPL activity and mass were com- 
pletely absent from media incubated with untransfected 
cells as well as cells transfected with plasmids lacking LPL 
cDNA (pCMV). Table 2 summarizes the concentration 
TABLE 2. Intracellular and media concentration of lipoprotein 
lipase in transfected 293 cells 
Vector 
% of Total LPL 
Media Intracellular in Media 
yg/plafe &Pate % 
pCMV-NL 9111 k 2918 1312 k 480 87.4 
pCMV-410 6166 k 636 1893 k 591 76.5 
pCMV-447 15820 f 3672 2329 + 284 87.2 
pCMV-4101447 9962 + 2725 1560 504 86.5 
of LPL present intracellularly and in the media of cells 
transfected with the LPL4Io, LPL447, or LPL4'o'447 mu- 
tant plasmids. Significant amounts of normal as well as all 
three mutant LPLs were detected in the transfection 
media. 
The specific activity of the expressed LPL present in 
the transfection media using either triolein or tributyrin 
substrates is summarized in Table 3. Transfection with 
the normal LPL construct, pCMV-NL, resulted in 
significant expression of an active enzyme with a specific 
activity of 263.2 nmol/pg per min using triolein as sub- 
strate. The specific activities of the expressed LPL4I0 and 
LPL447 were reduced to 11% and 70% of normal LPL, 
respectively. Unlike LPL4"J and LPL447, which retained 
some residual enzyme activity, LPL4'o/447 was completely 
inactive, thus establishing the functional significance of 
the combined mutations. 
Similar results were obtained when the LPL activity in 
the media was tested using the water-soluble lipid sub- 
strate, tributyrin (Table 3). Hydrolysis of tributyrin, a 
water-soluble short-chain triglyceride substrate, is in- 
dependent of enzyme-lipid interaction and reflects the 
catalytic function of the enzyme. The mutants LPLQ'O, 
LPL4+7, and LPL4'o/447 exhibited a reduction in esterase 
specific activities (23%, 74%, and 5% of normal, respec- 
tively) that was similar to that observed when triolein was 
used as substrate. Thus, there was no significant differ- 
ence in the ability of either mutant to hydrolyze triolein 
or tributyrin, suggesting that the two mutations do not 
preferentially disrupt the lipid-binding properties of 
LPL4Io and LPL447. The presence of both mutations, 
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TABLE 3. Mass and hydrolyzing activity of media from 293 cells transfected with normal and mutant lipoprotein lipase 
Triolein Tributyrin 
Specific Specific 
Vector Mass" Activity' Activity" Activity Activity 
ng/ml nmol/pl/min nmoUpg/min nmol/p Vmin nmol/pg/min 
pC MV -N L 473 f 64 124.5 f 3.88 263.2 2.13 f 0.47 4.50 
pCMV-410 406 i 89 12.28 f 1.35 30.2 0.42 + 0.06 1.03 
pCMV-447 805 f 112 149.1 f 4.08 185.2 2.67 f 0.14 3.32 
pCMV-410/447 555 i 89 0 0 0.13 f 0.03 0.23 
LPL mass and activity in media from untransfected cells was 0 and 2.86 f 0.35, respectively. LPL mass and activity in media of cells transfected 
"LPL mass and activity were calculated after subtraction of background values obtained from media of untransfected cells. 
with parent vector (pCMV) were 0 and 3.14 f 0.52, respectively. 
however, eliminated the ability of the mutant enzyme to 
hydrolyze both emulsified and hydrosoluble substrates. 
The effect of the Gl~4~O+Val s well as SerM7+Ter mu- 
tations on the heparin binding properties of LPL was ana- 
lyzed by heparin-Sepharose affinity chromatography us- 
ing a linear NaCl elution gradient (Fig. 3). Consistent 
with previous studies that indicate that normal LPL 
elutes primarily as two separate immunoreactive peaks 
consisting of a functional LPL dimer and an inactive LPL 
monomer (41), normal expressed LPL eluted at two 
different peak NaCl concentrations of approximately 1.2 
M and 0.7 M (bottom panel, Fig. 3). LPL activity was as- 
sociated only with the 1.2 M fraction. Analysis of the mu- 
tant enzymes revealed that most of the LPL4l0 and a sig- 
nificant proportion of LPL447 eluted with the low affinity 
inactive 0.7 M LPL peak (top and middle panels, Fig. 3). 
In contrast, active LPL4Io and LPL447 were detected in 
the 1.2 M elution fractions at a position similar to that of 
normal active LPL. The specific activities of these active 
LPL4Io and LPL447 fractions were similar to that of nor- 
mal LPL (0.2-0.4 nmolhg per min). 
DISCUSSION 
LPL is a complex enzyme that consists of multiple 
functional domains required for activity. Recent studies 
investigating the structure-function relationship of differ- 
ent LPL domains have provided new insights into LPL 
function (13-15, 42). Thus, the N-terminal region of LPL 
appears to be essential for interaction of LPL with its 
cofactor, apoC-11, as well as far the enzyme's catalytic 
function. In addition, the loop covering the catalytic site 
of LPL is important for the hydrolysis of lipid substrates 
(15). Although recent studies (13, 14) have indicated that 
the C-terminal domain plays a role in mediating heparin 
binding and is essential for the interaction of the enzyme 
with its lipid substrates, the functional role of the C- 
terminal domain of LPL remains to be elucidated. 
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Fig. 3. Heparin-Sepharose affinity chromatography of normal LPL 
and mutant LPL. The elution profile of LPL+lo, LPL447, and normal 
LPL is illustrated. LPL mass and activity are indicated by the closed and 
open circles, respectively. 
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In rhis report we describe a patient presenting with 
familial chylomicronemia due to unique mutations lo- 
cated in the C-terminal domain of LPL which provide 
new insights into a potential role of the C-terminal do- 
main of LPL in LPL-dimer formation. DNA sequencing 
and restriction enzyme digestion of proband PCR- 
amplified genomic DNA indicate that the patient is 
homozygous for two mutations: an A-tT transversion at 
nucleotide 1484 producing a Glu-+Val substitution at 
residue 410 and a C-+G transversion at nucleotide 1595 
resulting in the nonsense mutation Ser447-+Ter. Gh410 is 
conserved in all the LPLs described from different species 
(mouse, bovine, guinea pig, and chicken) as well as in the 
human and the rat HL (9, 43). The analogous residue in 
human pancreatic lipase is located within the loop con- 
necting the P-strands 5 and 6 in the C-terminus of PL 
corresponding to a stretch of amino acids highly con- 
served among all the described mammalian lipases (Fig. 
4) (16, 43). 
Residue 447, on the other hand, is not conserved in hu- 
man PL indicating it may not be essential for lipase func- 
tion. In fact, previous reports have described this muta- 
tion in the LPL gene of normotriglyceridemic healthy 
subjects that are either heterozygous or homozygous for 
the defect. In addition, the allelic frequency of the 
Ser447-+Ter substitution in two different normal Cauca- 
sian populations is fairly high, 8% and 17%, respectively 
(36, 37), suggesting that LPL447 may represent a normal 
functional LPL variant. 
In order to establish the functional significance of the 
GIu4"J-+Val and Ser4474Ter mutations, we expressed the 
mutant enzymes in human embryonal kidney 293 cells. 
Transient transfection of plasmids containing the LPL 
cDNAs for either the Ser447--tTer or Glu410-+Val substitu- 
tions resulted in the synthesis of mutant enzymes with 
reduced but significant residual activity of 70% and 1170, 
respectively. The reduction of activity detected in LPL4lo 
is similar to that of a previously described clinically 
significant mutant LPL172 (44) that retained 24% of nor- 
mal LPL function. In contrast, LPL4'o'447 mutant was 
completely inactive against either substrate. Thus, our ex- 
pression studies indicate that the combined defects in 
LPL410'447 are responsible for the patient's clinical presen- 
tation with hypertriglyceridemia and chylomicronemia. 
Consistent with previous studies (36),  expression of the 
single mutant, LPL447, resulted in the synthesis of an en- 
zyme exhibiting only a slight reduction in LPL specific 
activity (70% that of normal) using triolein as substrate. 
Our studies indicate that the specific tributyrin hydrolyz- 
ing activity of LPL447 was reduced to a degree similar to 
that observed in the specific triolein hydrolyzing activity. 
The mild impairment of the LPL function due to the 
Ser447-tTer mutation, particularly in heterozygotes, does 
not appear sufficient to significantly modify in vivo 
triglyceride metabolism. Thus, the father of our proband, 
4 
41 0 
Fig. 4. Schematic representation of the a-carbon backbone of human 
pancreatic lipase (IO). The proposed location of the amino acid residues 
of the catalytic triad and the amino acid substitution in LPL"O 
( G l ~ ~ ~ o - V a l )  are indicated in the figure based on the sequence homol- 
ogy of pancreatic and lipoprotein lipase; (---) disulfide bonds; (0) high- 
lighted amino acid residues. 
although a carrier for the mutant allele, is normolipi- 
demic while the mother is only slightly hypertriglyceri- 
demic. It is possible that other genetic or environmental 
factors affecting lipid metabolism are required for the ex- 
pression of hyperlipidemia in these individuals (45, 46). 
Expression of the LPL410 mutant alone resulted in the 
production of an enzyme exhibiting a more severe loss of 
activity. Thus, the triolein and tributyrin specific activi- 
ties were reduced to 11% and 22% that of normal, respec- 
tively. As with LPL447, the substitution of Glu410 by Val 
did not appear to preferentially disrupt the lipid binding 
domain of LPL as the efficiency of hydrolysis of either 
substrate was similarly altered. 
To further explore the underlying mechanism resulting 
in a 90% and 30% loss of activity in LPL4'* and LPL447, 
respectively,. we analyzed their heparin binding properties 
1558 Journal of Lipid Research Volume 35, 1994 
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on heparin-Sepharose affinity chromatography. Previous 
studies have indicated that normal LPL elutes as two im- 
munoreactive peaks at approximately 0.7 M and 1.2 M 
NaCl, representing the inactive LPL monomer and active 
dimer LPL (41), respectively. Functional LPL4I0 and 
LPL447, with a specific activity similar to that of normal 
LPL, eluted at the same position as the normal active 
LPL, suggesting the presence of functional LPL4lo and 
LPL447 dimers. Most of LPL410 as well as a significant 
amount of LPL447 eluted as an  inactive enzyme at a posi- 
tion in the gradient similar to that of the normal LPL 
monomer (0.7 M NaCl). Based on these findings we 
speculate that the majority of LPL4l0 as well as a 
significant proportion of LPL447 were present in the 
monomeric, inactive state. The  presence of a fully func- 
tional mutant enzyme indicates that the G1u4l0+Val and 
Ser447 +Ter substitutions do  not directly disrupt the cata- 
lytic function of the mutant enzyme. Instead, our studies 
indicate that the loss of activity in both mutants may 
result from an  inability to either generate or maintain the 
LPL dimer, resulting in a shift of the normal LPL monomer- 
dimer equilibrium in favor of the inactive LPL monomer. 
In  contrast to the partial loss of enzyme activity ob- 
served in LPL4l0 and LPL447, combined mutant 
LPL4’o’447 was completely inactive against either triolein 
or  tributyrin substrates. Thus, we postulate that the 
presence of both carboxyl-terminal mutations in 
LPL410’447 may further disrupt the ability of the com- 
bined mutant enzyme to form and/or maintain a stable 
dimer, leading to complete enzyme inactivation. Alterna- 
tively, the combined mutation in LPL410’447 may lead to 
major conformational changes in LPL structure resulting 
in overall disruption of LPL function. Recently, charac- 
terization of exon 5 missense mutations located in the N- 
terminus of LPL by Hata et al. (47) has indicated that 
these substitutions lead to a disruption of the LPL dimer. 
The  present study represents the first description of a mu- 
tation in the C-terminus of LPL affecting monomer- 
dimer equilibrium and suggests that the C-terminal do- 
main of LPL and specifically residue Glu410 may play an 
important role in LPL dimer formation. 
I n  summary, we have identified a unique missense mu- 
tation located in the C-terminal domain of LPL resulting 
in a Glu-tVal substitution at  residue 410 that leads to a 
loss of enzymatic activity. The  Glu4’*+ Val substitution 
does not directly disrupt the catalytic, heparin, or lipid 
binding properties of the mutant enzyme but results in a 
shift of the LPL monomer-dimer equilibrium in favor of 
the formation of the LPL monomer. The  simultaneous 
presence of the Ser447+Ter mutation potentiates the effect 
of the first defect resulting in the synthesis of a completely 
inactive LPL. O u r  studies indicate that the C-terminal 
domain of LPL may play a n  important role in LPL dimer 
formation. I 
Manuscript recewed 22 July 1993 and in reuised form 24 February 1994. 
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